Biocon Biologics Extends Civica Partnership: Affordable Insulin for Millions of Americans
Americans with diabetes face a brutal choice: pay exorbitant insulin prices or ration life-saving medication and risk severe health complications. This isn’t hyperbole—patients regularly skip doses, stretch supplies dangerously thin, or simply go without because insulin costs have spiraled beyond affordability for millions. Biocon Biologics, a global biosimilars leader, has extended its partnership with US-based […]










